Mumbai (Maharashtra) [India], January 29: Sudarshan Pharma Industries Ltd. today announced robust financial results for Q3FY26 and a strategic step to broaden its global footprint with the incorporation of a wholly-owned subsidiary in Poland. The company recorded net sales of Rs 168.01 crore in Q3FY26, a 16% increase over Q3FY25, while net profit rose 51% to Rs 4.36 crore, reflecting healthy operational momentum and improving margins. For the nine-month period ended in FY26, Sudarshan Pharma delivered a 40% rise in net sales to Rs 482.14 crore and a 67% jump in net profit to Rs 12.58 crore versus 9MFY25. On an annual basis, the company's FY25 results also demonstrated steady growth, with net sales up 9% to Rs 505 crore and net profit higher by 45% to Rs 16 crore compared to FY24.
Building on its financial strength and long-term growth trajectory, Sudarshan Pharma has expanded into Europe by establishing Sudarshan Pharma Company Poland Limited Liability in Warsaw. Following board approval in February 2025, the company invested PLN 5,000 for full ownership of the new entity, which will focus on the manufacture of chemicals, fertilisers, and plastics, as well as the wholesale distribution of pharmaceutical products. Management expects the Polish subsidiary to help deepen customer relationships across the European market and support the company's ambitions in the international chemical and agrochemical sectors.
Sudarshan Pharma's market capitalisation stands at over Rs 400 crore, underpinned by a strong performance record that includes an impressive 70% CAGR in profit over the last five years. The stock has recovered from its 52-week low—rising 9.3% from Rs 18.53 per share—and has delivered multibagger returns of 155% over two years, indicating solid investor confidence in its growth story. Founded in 2008 and headquartered in Mumbai, Sudarshan Pharma Industries Ltd. is a manufacturer of Active Pharmaceutical Ingredients (APIs) and a trader in chemicals and solvents. The company offers a diversified product mix spanning bulk chemicals, intermediates and finished formulations, with several products marketed under its “R” trademark, including widely recognised brands such as Love Birds and Metfocal. Sudarshan Pharma serves both the domestic market and international customers across Southeast Asia, the Middle East and North Africa, and the new European foothold is expected to enhance its global distribution and manufacturing capabilities.
Disclaimer:This article is for informational purposes only and does not constitute financial advice.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor